FDA clears Aerobiotix system to clean air inside hospitals

2021-01-25
Aerobiotix announced today that it received FDA 510(k) clearance for its Aerocure-MD medical air purification system. Miamisburg, Ohio-based Aerobiotix’s Aerocure-MD platform received FDA labeling to destroy microorganisms in the air by exposure to ultraviolet radiation and also remove particles in from the air via HEPA filtration, according to a news release. Aerocure-MD is designed for mobile, high-volume air decontamination applications in healthcare spaces including acute care areas, contaminated storage and handling areas and long-term healthcare facilities. The system uses a shielded internal ultraviolet system to prevent potentially hazardous exposure of personnel and material to ultraviolet rays. The company said it submitted independent data demonstrating effectiveness against viral and bacterial aerosols, along with particulate contamination to support clearance. “This clearance represents an important regulatory validation of our technology as we expand our footprint to cover all areas of healthcare,” Aerobiotix CEO Dr. David Kirschman said in the release. “The growing challenge of airborne healthcare-acquired infections, including SARS-CoV-2, underscores the need for medical devices with rigorously investigated, peer-reviewed performance against airborne organisms in real-world clinical environments.”
适应症
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。